Paper Details

  1. Home
  2. Paper Details

Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.

Author: SmithIan E

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Letrozole, an aromatase inhibitor, has been shown to be more effective than tamoxifen in the treatment of advanced breast cancer. Letrozole is superior to tamoxifen in terms of time to progression, objective response, and clinical benefit in both first-line and neoadjuvant treatment settings.
Paper Details　
Original Abstract of the Article :
Letrozole, a third generation aromatase inhibitor, has been compared with tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. In a first-line trial in advanced disease, 939 post menopausal women were randomised double blind to receive treatment with letrozole 2.5 mg dail...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0960-0760(03)00369-8

データ提供：米国国立医学図書館（NLM）

Letrozole vs. Tamoxifen: A Battle in the Desert of Breast Cancer Treatment

In the vast and unforgiving desert of breast cancer treatment, researchers are constantly seeking new weapons to combat this formidable foe. This study explores the efficacy of letrozole, a third-generation aromatase inhibitor, compared to tamoxifen, a well-established treatment for advanced breast cancer.

The study found that letrozole outperformed tamoxifen in terms of time to progression, objective response, and clinical benefit. Letrozole's superiority was observed across various patient characteristics, suggesting that it may offer a more potent therapeutic option. While there was no significant difference in overall survival between the two treatments, the study provides compelling evidence that letrozole should be considered a leading contender in the fight against advanced breast cancer.

A New Oasis in Breast Cancer Treatment: Letrozole Shows Promise

The results of this study indicate that letrozole holds promise as a powerful weapon in the fight against breast cancer. Its effectiveness in slowing disease progression and achieving objective responses suggests that it may offer a significant advantage over tamoxifen for certain patients. This discovery has implications for future clinical trials and treatment strategies.

Understanding the Sands of Breast Cancer Treatment: Letrozole Offers Hope

As a researcher who has witnessed the challenges of breast cancer treatment firsthand, I find this study encouraging. The promise of letrozole, coupled with the ongoing research into new treatments, offers hope for those battling this disease. I encourage patients to discuss the potential benefits and risks of letrozole with their healthcare providers to determine if it is the right option for them.

Dr. Camel's Conclusion

Letrozole emerged as a more effective treatment for advanced breast cancer than tamoxifen, demonstrating its potential as a valuable weapon in the fight against this disease. This study underscores the importance of ongoing research and the development of novel therapies to improve treatment outcomes for breast cancer patients.
Date :
  1. Date Completed 2004-01-27
  2. Date Revised 2019-09-01
Further Info :

Pubmed ID

14623523

DOI: Digital Object Identifier

10.1016/s0960-0760(03)00369-8

Related Literature

Article Analysis
・Effects of letrozole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.